These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15039597)

  • 1. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
    Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells.
    Larsen SS; Heiberg I; Lykkesfeldt AE
    Br J Cancer; 2001 Mar; 84(5):686-90. PubMed ID: 11237391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor.
    Li Y; Cook KL; Yu W; Jin L; Bouker KB; Clarke R; Hilakivi-Clarke L
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
    Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
    Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
    Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
    Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.
    Yang L; Yang J; Venkateswarlu S; Ko T; Brattain MG
    J Cell Physiol; 2001 Sep; 188(3):383-93. PubMed ID: 11473365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro.
    James SY; Mercer E; Brady M; Binderup L; Colston KW
    Br J Pharmacol; 1998 Nov; 125(5):953-62. PubMed ID: 9846632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
    Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
    Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
    Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach.
    Santos-Martínez N; Díaz L; Ordaz-Rosado D; García-Quiroz J; Barrera D; Avila E; Halhali A; Medina-Franco H; Ibarra-Sánchez MJ; Esparza-López J; Camacho J; Larrea F; García-Becerra R
    BMC Cancer; 2014 Mar; 14():230. PubMed ID: 24678876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.
    Achounna AS; Ordaz-Rosado D; García-Quiroz J; Morales-Guadarrama G; Milo-Rocha E; Larrea F; Díaz L; García-Becerra R
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin treatment of antiestrogen-resistant breast cancer cells.
    Larsen MS; Yde CW; Christensen IJ; Lykkesfeldt AE
    Int J Oncol; 2012 Nov; 41(5):1863-70. PubMed ID: 22961366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
    Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
    Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells.
    James SY; Mackay AG; Binderup L; Colston KW
    J Endocrinol; 1994 Jun; 141(3):555-63. PubMed ID: 8071654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.